Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Phase II Dose-Exploration and Expansion Study to Evaluate TT-01488 Tablets in Combination With an Anti-CD20 Monoclonal Antibody-Containing Regimen for the Treatment of Mantle Cell Lymphoma.

NCT07855016 is registered in ClinicalTrials.gov with TransThera Sciences (Nanjing), Inc. as lead sponsor.

NCT NCT07855016
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07855016 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Phase II Dose-Exploration and Expansion Study to Evaluate TT-01488 Tablets in Combination With an Anti-CD20 Monoclonal Antibody-Containing Regimen for the Treatment of Mantle Cell Lymphoma.
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 10, 2026
Completion date
October 10, 2029
Enrollment
188 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma (mcl)